Application of GLP-1 analogs with higher plasma levels and longer half-life activates the above-mentioned anti-inflammatory pathways and ameliorates adverse effects of an exaggerated inflammatory response in CLP-induced sepsis. This evidence concerns the gene GLP1R and Sepsis.